A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03446962 In Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Ascrinvacumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 20 Jun 2016 Results of part II of this study (n=24) published in the Annals of Oncology
- 11 Dec 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.